JP2020528447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528447A5 JP2020528447A5 JP2020504405A JP2020504405A JP2020528447A5 JP 2020528447 A5 JP2020528447 A5 JP 2020528447A5 JP 2020504405 A JP2020504405 A JP 2020504405A JP 2020504405 A JP2020504405 A JP 2020504405A JP 2020528447 A5 JP2020528447 A5 JP 2020528447A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- compound
- composition according
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114928A JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17315006.1A EP3434692A1 (en) | 2017-07-24 | 2017-07-24 | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| EP17315006.1 | 2017-07-24 | ||
| PCT/EP2018/070064 WO2019020643A1 (en) | 2017-07-24 | 2018-07-24 | COMPOUND BINDING SPECIFICALLY TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114928A Division JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528447A JP2020528447A (ja) | 2020-09-24 |
| JP2020528447A5 true JP2020528447A5 (enExample) | 2021-09-02 |
Family
ID=59626538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504405A Pending JP2020528447A (ja) | 2017-07-24 | 2018-07-24 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
| JP2023114928A Pending JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114928A Pending JP2023134636A (ja) | 2017-07-24 | 2023-07-13 | 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210087290A1 (enExample) |
| EP (2) | EP3434692A1 (enExample) |
| JP (2) | JP2020528447A (enExample) |
| CN (1) | CN111108127A (enExample) |
| AU (1) | AU2018308649A1 (enExample) |
| CA (1) | CA3070756A1 (enExample) |
| WO (1) | WO2019020643A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020205753B2 (en) | 2019-01-11 | 2025-05-29 | Omeros Corporation | Methods and compositions for treating cancer |
| US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
| EP4054714A4 (en) * | 2019-11-07 | 2023-12-06 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS RELATING TO SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS |
| EP3943505A1 (en) * | 2020-07-22 | 2022-01-26 | Encefa | Cd38-binding cd31 peptides and uses thereof |
| WO2022152823A1 (en) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| PE20232047A1 (es) | 2021-01-29 | 2023-12-27 | Boehringer Ingelheim Int | Quinolinas y azaquinolinas como inhibidores de cd38 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| JP7782720B2 (ja) | 2022-10-28 | 2025-12-09 | 日本精工株式会社 | 回転支持装置、及び軸支持装置の支持機構位置調整機構 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| JP6093696B2 (ja) * | 2010-06-09 | 2017-03-08 | ゲンマブ エー／エス | ヒトｃｄ３８に対する抗体 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| WO2016024246A1 (en) | 2014-08-14 | 2016-02-18 | Universita' Degli Studi Di Roma 'la Sapienza' | A therapeutic use of naadp and/or tcp2 antagonists |
| BR112017004614A2 (pt) * | 2014-09-09 | 2018-02-27 | Janssen Biotech, Inc. | terapias de combinação com anticorpos anti-cd38 |
| WO2016210223A1 (en) * | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| MY187033A (en) | 2015-06-24 | 2021-08-27 | Japan Chem Res | Anti-human transferrin receptor antibody permeating blood-brain barrier |
| US10722529B2 (en) * | 2015-12-03 | 2020-07-28 | Temple University—Of the Commonwealth System of Higher Education | Modulation of NAD+ metabolic pathways for treatment of disease |
-
2017
- 2017-07-24 EP EP17315006.1A patent/EP3434692A1/en not_active Withdrawn
-
2018
- 2018-07-24 CN CN201880061584.XA patent/CN111108127A/zh active Pending
- 2018-07-24 US US16/633,749 patent/US20210087290A1/en active Pending
- 2018-07-24 CA CA3070756A patent/CA3070756A1/en active Pending
- 2018-07-24 JP JP2020504405A patent/JP2020528447A/ja active Pending
- 2018-07-24 AU AU2018308649A patent/AU2018308649A1/en not_active Abandoned
- 2018-07-24 EP EP18753069.6A patent/EP3658586A1/en not_active Withdrawn
- 2018-07-24 WO PCT/EP2018/070064 patent/WO2019020643A1/en not_active Ceased
-
2023
- 2023-07-13 JP JP2023114928A patent/JP2023134636A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528447A5 (enExample) | ||
| Pradhan et al. | Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis | |
| IL261658B2 (en) | Neuroactive steroids, preparations and their uses | |
| US20010018053A1 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
| WO2006002177A3 (en) | Interferon alpha receptor 1 antibodies and their uses | |
| BRPI0417959A (pt) | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| CN113490505A (zh) | 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体 | |
| TWI717848B (zh) | 抗體於治療神經退化性疾病的用途 | |
| JP2013542266A (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法 | |
| JP2019534327A5 (enExample) | ||
| US20200262864A1 (en) | Deuterated forms of aminosterols and methods of using the same | |
| JP2013542267A (ja) | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 | |
| JP2023507569A (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| Osinalde et al. | Impaired proteostasis in rare neurological diseases | |
| Robbins et al. | Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome | |
| JP6347807B2 (ja) | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 | |
| Pérez de Llano et al. | Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. | |
| Kastenbauer et al. | No evidence of type 1 or type 3 hypersensitivity mechanism in amoxicillin/clavulanic acid induced aseptic meningitis | |
| Panzer et al. | Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders | |
| Meng et al. | Pediatric Anti-Glyr Antibody-Associated Progressive Encephalomyelitis with Rigidity and Myoclonus-A Case Report and Literature Review | |
| Hardjo Lugito et al. | Worsening muscle weakness in myasthenia gravis patient suffering dengue infection | |
| Dalmau et al. | Paraneoplastic syndromes causing movement disorders | |
| Panzer et al. | Anti-NMDA Receptor Encephalitis | |
| Khadilkar et al. | Chronic inflammatory demyelinating polyradiculoneuropathy |